StarkAge Therapeutics will present preclinical data for our lead ADC program, called STX-1, targeting DPP4 positive cancer and senescent cancer cells at the upcoming American Association for Cancer Research’s Annual Meeting.

Eric Angevin, Scientific Advisor, and Benjamin Le Calvé, CSO, will be in San Diego, highlighting our in vitro and in vivo results in a poster presentation on April 8, 2024.